Skip to main content
Clinical Trials/NCT02889068
NCT02889068
Completed
Not Applicable

Targeted Next Generation Sequencing and Intellectual Disability

Central Hospital, Nancy, France1 site in 1 country40 target enrollmentJuly 2015

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Intellectual Disability
Sponsor
Central Hospital, Nancy, France
Enrollment
40
Locations
1
Primary Endpoint
Percentage of patients with certain etiologic diagnosis established with NGS
Status
Completed
Last Updated
8 years ago

Overview

Brief Summary

The purpose is to determine the benefit of next generation sequencing (NGS) targeted on genes involved in intellectual disability for etiologic diagnosis of intellectual disabilities. In other words, it concerns the number of patients whose etiologic diagnosis will be established with NGS and could not with common techniques. Actually, the molecular etiology of intellectual disability is crucial to calculate the risk of recurrence and allows the perinatal diagnosis to these families.

Secondary purposes are:

  1. To determine the place of NGS in the strategy of etiologic diagnosis of intellectual disability, to determine the order of analyses performed for a patient with intellectual disability without clinical signs.
  2. To evaluate the number of variants with unknown significance and thus non-usable for genetic counselling without supplementary analysis.
  3. To determine the number of samples that can be at most pooled keeping a good efficacy of capture and results with suitable read depth
  4. To determine the possibility of detecting copy number variations (CNVs) in genes of interest with NGS
  5. To establish genotype/phenotype correlations for each gene for which a mutation has been identified
  6. To optimize the software pipelining for a rapid analysis for diagnosis.
Registry
clinicaltrials.gov
Start Date
July 2015
End Date
January 30, 2017
Last Updated
8 years ago
Study Type
Observational
Sex
All

Investigators

Sponsor
Central Hospital, Nancy, France
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Moderate or severe intellectual disability
  • Availability of patient and parent DNA
  • No etiologic diagnosis with standard approaches: negative fragile X, normal pangenomic 180K and 1M array-CGH
  • Informed consent of person having parental authority

Exclusion Criteria

  • Non availability of parent DNA
  • Patient lost to follow-up

Outcomes

Primary Outcomes

Percentage of patients with certain etiologic diagnosis established with NGS

Time Frame: day 0

Secondary Outcomes

  • Percentage of patients with etiologic diagnosis established with NGS or with other techniques (array-CGH)(day 0)
  • Obtained read depth according to number of pooled samples(day 0)
  • Percentage of patients with variant with unknown significance, needing supplementary analyses to prove its involvement in intellectual disability(day 0)
  • CNVs detected with NGS or array-CGH (reference technique for CNV detection).(day 0)
  • Clinical phenotype for each gene for which a causal mutation is identified by NGS(day 0)
  • Time of analysis of NGS raw data(day 0)

Study Sites (1)

Loading locations...

Similar Trials